The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

oxamniquine     [7-nitro-2-[(propan-2- ylamino)methyl]-1,2...

Synonyms: Mansil, Vansil, Oxamniquina, Oxaminiquine, Oxamniquinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of oxamniquine


Psychiatry related information on oxamniquine


High impact information on oxamniquine


Chemical compound and disease context of oxamniquine


Biological context of oxamniquine

  • The meeting addressed general issues of the organization of public health services, but focused on schistosomiasis where the development of effective, single oral dose chemotherapy (using oxamniquine or praziquantel) is seen as a realistic intervention for large-scale control throughout the 74 endemic countries [15].
  • Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan [16].
  • A significant correlation between oxamniquine AUC and T1/2 suggests that its elimination may be non-linear [16].
  • On days 70 and 160 two other groups of infected mice were treated with 400 mg/kg of oxamniquine and portal pressure was measured 90 days later (160 and 250 days after infection) [17].
  • The DNA fraction from sensitive worms contained radioactive oxamniquine at a level corresponding to about 1 drug molecule per 50,000 base pairs, while the DNA from resistant worms contained essentially no drug [18].

Anatomical context of oxamniquine

  • The central nervous system effects of oxamniquine are reviewed with respect to its possible epileptogenic effects [19].
  • Twenty male patients (mean age 23 years) with Schistosoma mansoni infections (mean egg count 429 +/- 311/g feces) were each treated with oxamniquine orally in a single daily dose of 20 mg/kg for 3 consecutive days [20].
  • A characteristic feature of Ro11-3128 treatment in vitro is the formation of exudates and membranous blebs at the schistosomular surface; other drugs tested, such as Ro15-5458 and oxamniquine which are also effective against the skin stages but relatively ineffective in inducing protection, do not induce this reaction [21].
  • 1. The extent of metabolism of oxamniquine, 6-hydroxymethyl-7-nitro-2-isopropylaminomethyl-1,2,3,4-tetrahydroquinoline, in the gut of the dog has been studied using an intestinal preparation which allows collection of the outflow from the portal vein [22].
  • Oxamniquine significantly increased the activities of serum transaminases and alkaline phosphatase and caused necrosis in some liver cells [23].

Associations of oxamniquine with other chemical compounds


Gene context of oxamniquine

  • In contrast, only 1 serum was synergistic with oxamniquine when administered with drug and both sera were synergistic when given 6-9 days after drug treatment [28].
  • The sera from 15 infected patients before and 2 years after treatment with oxamniquine (n = 30) recognized bands ranging in molecular weight from 9 to 200 Kd [29].
  • 7. The infection of mice with 30 cercariae of S. mansoni induced portal hypertension, both during the acute and chronic phases and treatment with oxamniquine caused portal pressure to return to normal levels [17].
  • Combined low doses of praziquantel and oxamniquine were tested against different stages of Schistosoma mansoni in infected Swiss albino mice [30].
  • The prophylactic and curative effects of praziquantel and oxamniquine on a Saudi Arabian strain of Schistosoma mansoni in MF-1 mice were assessed [31].

Analytical, diagnostic and therapeutic context of oxamniquine

  • At one extreme the development of effective single-dose oral drugs such as praziquantel and oxamniquine makes mass chemotherapy a practical option [32].
  • The reported occurrence of drug-resistant schistosomes after treatment with oxamniquine and praziquantel suggests strict monitoring of such phenomena and encourages renewed efforts toward the development of multiple drugs against this human parasite [9].
  • Infected recipients and donors with active lesions were treated at least 1 month before transplantation by combined antischistosomal drugs (praziquantel and oxamniquine) [33].
  • The serologic activity of a cationic fraction (denoted CEF6) of Schistosoma mansoni soluble egg antigen was compared in an ELISA with that of the unpurified soluble egg antigen for the ability to detect human infections and for the prediction of chemotherapeutic success in patients followed up to 5 years post-treatment with oxamniquine [34].
  • Treatment of the animals with a schistosomicidal compound (oxamniquine) almost completely abolished the immunosuppression [35].


  1. Manson's schistosomiasis in Brazil: 11-year evaluation of successful disease control with oxamniquine. Sleigh, A.C., Hoff, R., Mott, K.E., Maguire, J.H., da França Silva, J.T. Lancet (1986) [Pubmed]
  2. Treatment of schistosome-induced glomerulonephritis. A case report and review of the literature. Ott, B.R., Libbey, N.P., Ryter, R.J., Trebbin, W.M. Arch. Intern. Med. (1983) [Pubmed]
  3. Clinical characteristics and response to therapy in Egyptian children heavily infected with Schistosoma mansoni. Strickland, G.T., Merritt, W., El-Sahly, A., Abdel-Wahab, F. J. Infect. Dis. (1982) [Pubmed]
  4. Mutagenic activities in vitro and in vivo of five antischistosomal compounds. Batzinger, R.P., Bueding, E. J. Pharmacol. Exp. Ther. (1977) [Pubmed]
  5. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Da Silva, L.C., Carrilho, F.J. Gastroenterol. Clin. North Am. (1992) [Pubmed]
  6. Schistosoma mansoni: effects of bromolysergic acid diethylamide, verapamil, and Ca2+-free solution on the motor activity of the isolated male worm induced by electrical stimulation and oxamniquine. Soares de Moura, R., Rozental, R., Claudio-da-Silva, T.S. Exp. Parasitol. (1987) [Pubmed]
  7. Evolution of the schistosomal hepatic lesions in mice after curative chemotherapy. Andrade, Z.A., Grimaud, J.A. Am. J. Pathol. (1986) [Pubmed]
  8. Drug resistance in schistosomes. Cioli, D., Pica-Mattoccia, L., Archer, S. Parasitol. Today (Regul. Ed.) (1993) [Pubmed]
  9. Antischistosomal drugs: past, present ... and future? Cioli, D., Pica-Mattoccia, L., Archer, S. Pharmacol. Ther. (1995) [Pubmed]
  10. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Rihet, P., Demeure, C.E., Bourgois, A., Prata, A., Dessein, A.J. Eur. J. Immunol. (1991) [Pubmed]
  11. Evaluation of oral therapy of mansonial schistosomiasis in the Sudan using single and multiple doses of hycanthone and oxamniquine drugs. Magzoub, M., Adam, S.E. J. Pharmacol. Exp. Ther. (1978) [Pubmed]
  12. Oxamniquine versus niridazole for treatment of uncomplicated Schistosoma mansoni infection. Kilpatrick, M.E., El Masry, N.A., Bassily, S., Farid, Z. Am. J. Trop. Med. Hyg. (1982) [Pubmed]
  13. The acute toxicity of oxamniquine in rats; a sex-dependent hepatotoxicity. Gregory, M., Monro, A., Quinton, M., Woolhouse, N. Arch. Toxicol. (1983) [Pubmed]
  14. Interventions for treating schistosomiasis mansoni. Saconato, H., Atallah, A. Cochrane database of systematic reviews (Online) (2000) [Pubmed]
  15. The Organization of schistosomiasis control programmes. Liese, B. Parasitol. Today (Regul. Ed.) (1986) [Pubmed]
  16. Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan. Daneshmend, T.K., Homeida, M.A. J. Antimicrob. Chemother. (1987) [Pubmed]
  17. On the increase of portal pressure during the acute and chronic phases of murine schistosomiasis mansoni and its reversibility after treatment with oxamniquine. Costa, G., Aguiar, B.G., Coelho, P.M., Cunha-Melo, J.R. Acta Trop. (2003) [Pubmed]
  18. Binding of oxamniquine to the DNA of schistosomes. Pica-Mattoccia, L., Cioli, D., Archer, S. Trans. R. Soc. Trop. Med. Hyg. (1989) [Pubmed]
  19. Seizures and electroencephalograph changes associated with oxamniquine therapy. Keystone, J.S. Am. J. Trop. Med. Hyg. (1978) [Pubmed]
  20. Treatment of complicated schistosomiasis mansoni with oxamniquine. Bassily, S., Farid, Z., Higashi, G.I., Watten, R.H. Am. J. Trop. Med. Hyg. (1978) [Pubmed]
  21. Resistance induced by drug abbreviated Schistosoma mansoni infections: treatment with the drug Ro11-3128 leads to enhanced antigen presentation. Smith, D.A., Bickle, Q.D., Kaye, P.M. Immunology (1994) [Pubmed]
  22. The metabolism of oxamniquine in the gut wall. Kaye, B., Roberts, D.W. Xenobiotica (1980) [Pubmed]
  23. Effects of certain antibilharzial and contraceptive drugs on liver functions in rats. Farag, R.S., Youssef, A.M., Nagib, A.M., Ibrahim, M.H. Contraception. (1982) [Pubmed]
  24. Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Ferrari, M.L., Coelho, P.M., Antunes, C.M., Tavares, C.A., da Cunha, A.S. Bull. World Health Organ. (2003) [Pubmed]
  25. Computer-aided optimisation of drug enantiomer separation in chiral high-performance liquid chromatography. Fell, A.F., Noctor, T.A., Mama, J.E., Clark, B.J. J. Chromatogr. (1988) [Pubmed]
  26. Resolution of the enantiomers of oxamniquine by capillary electrophoresis and high-performance liquid chromatography with cyclodextrins and heparin as chiral selectors. Abushoffa, A.M., Clark, B.J. Journal of chromatography. A. (1995) [Pubmed]
  27. Schistosoma mansoni: chemotherapy of infections of different ages. Sabah, A.A., Fletcher, C., Webbe, G., Doenhoff, M.J. Exp. Parasitol. (1986) [Pubmed]
  28. Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody synergy. Fallon, P.G., Fookes, R.E., Wharton, G.A. Parasitology (1996) [Pubmed]
  29. Identification of a genus-specific Schistosoma mansoni soluble egg antigen reactive with the serum of infected patients. Hillyer, G.V., Nieves-Frau, L.L., Vazquez, G. Am. J. Trop. Med. Hyg. (1986) [Pubmed]
  30. Effect of combined low dose praziquantel and oxamniquine on different stages of schistosome maturity. Botros, S., Soliman, A., el-Gawhary, N., Selim, M., Guirguis, N. Trans. R. Soc. Trop. Med. Hyg. (1989) [Pubmed]
  31. Effects of praziquantel and oxamniquine on a Saudi Arabian strain of Schistosoma mansoni in mice. Ghandour, A.M., Banaja, A.A., Shalaby, I.M. J. Helminthol. (1990) [Pubmed]
  32. The economics of schistosomiasis chemotherapy. Prescott, N.M. Parasitol. Today (Regul. Ed.) (1987) [Pubmed]
  33. Impact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up. Mahmoud, K.M., Sobh, M.A., El-Agroudy, A.E., Mostafa, F.E., Baz, M.E., Shokeir, A.A., Ghoneim, M.A. Nephrol. Dial. Transplant. (2001) [Pubmed]
  34. Schistosoma mansoni cationic egg antigens (CEF6): immunoserology with oxamniquine-treated patients and involvement of CEF6 in the circumoval precipitin reaction. Dunne, D.W., Hillyer, G.V., Vazquez, G. Am. J. Trop. Med. Hyg. (1988) [Pubmed]
  35. Immunosuppression mediated by adult worms in chronic schistosomiasis mansoni. Mota-Santos, T.A., Tavares, C.A., Gazzinelli, G., Pellegrino, J. Am. J. Trop. Med. Hyg. (1977) [Pubmed]
WikiGenes - Universities